Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients.
Anna LeeChris LarckDonald C MoorePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
This study suggests obese patients receiving T-DM1 may require more treatment modifications secondary to adverse events compared to non-obese patients. Larger studies are needed to determine if obese patients are at higher risk for specific T-DM1-induced adverse events.
Keyphrases
- obese patients
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- weight loss
- metabolic syndrome
- type diabetes
- insulin resistance
- adipose tissue
- epidermal growth factor receptor
- glycemic control
- combination therapy
- weight gain
- high glucose
- drug induced
- skeletal muscle
- diabetic rats
- high fat diet induced
- smoking cessation
- endothelial cells